LLY

997.4

+0.67%↑

JNJ

204.78

+1.7%↑

ABBV

224.5

+0.54%↑

UNH

325.09

+0.39%↑

AZN

90.84

+0.94%↑

LLY

997.4

+0.67%↑

JNJ

204.78

+1.7%↑

ABBV

224.5

+0.54%↑

UNH

325.09

+0.39%↑

AZN

90.84

+0.94%↑

LLY

997.4

+0.67%↑

JNJ

204.78

+1.7%↑

ABBV

224.5

+0.54%↑

UNH

325.09

+0.39%↑

AZN

90.84

+0.94%↑

LLY

997.4

+0.67%↑

JNJ

204.78

+1.7%↑

ABBV

224.5

+0.54%↑

UNH

325.09

+0.39%↑

AZN

90.84

+0.94%↑

LLY

997.4

+0.67%↑

JNJ

204.78

+1.7%↑

ABBV

224.5

+0.54%↑

UNH

325.09

+0.39%↑

AZN

90.84

+0.94%↑

Home・Stock List・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Open

1.29

Buy Sell

Overview

Share price change

24h

Current

Min

1.25

Max

1.31

Key metrics
By Trading Economics
Income	17M -26M
EPS	-0.43
Profit margin	-2,190.837
Employees	171
EBITDA	19M -23M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+134.38% upside

Market Stats
By TradingEconomics
Market Cap	-24M 79M
Previous open	1.29
Previous close	1.29

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

1.43 / 1.6 Support & Resistance

Pliant Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

9 Dec 2025, 22:13 UTC

Earnings

GE Vernova Raises Outlook, Doubles Dividend on Energy Market Momentum

9 Dec 2025, 21:40 UTC

Earnings

GameStop Sales Fall as Collectibles Remain Only Bright Spot

9 Dec 2025, 18:51 UTC

Acquisitions, Mergers, Takeovers

Broadwood Partners Still Opposes Alcon's Higher Bid for Staar Surgical

9 Dec 2025, 16:57 UTC

Major Market Movers

Clear Secure Rises on Medicare Identity Verification Contract

9 Dec 2025, 23:46 UTC

Market Talk

Nikkei May Trade Rangebound Ahead of Fed Rate Decision -- Market Talk

9 Dec 2025, 23:46 UTC

Acquisitions, Mergers, Takeovers

Legend Holdings Stake in Lenovo Now at 32.34%

9 Dec 2025, 23:45 UTC

Acquisitions, Mergers, Takeovers

Legend Holdings: Remains Optimistic About Lenovo's Future Development Potential

9 Dec 2025, 23:44 UTC

Acquisitions, Mergers, Takeovers

Legend Holdings: Purchased Lenovo Shares at Average Price of HK$9.7653/Share

9 Dec 2025, 23:43 UTC

Acquisitions, Mergers, Takeovers

Legend Holdings: Acquired Lenovo Shares for Total Cash Consideration of HK$1.12B

9 Dec 2025, 23:43 UTC

Acquisitions, Mergers, Takeovers

Legend Holdings: Acquired 115.17M Lenovo Shares From Open Market Between Nov. 21 and Dec. 9

9 Dec 2025, 23:35 UTC

Market Talk

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

9 Dec 2025, 22:42 UTC

Earnings

PepsiCo Wants to Boost Sales, Cut Costs. The Street Is Doubtful. -- Barrons.com

9 Dec 2025, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

9 Dec 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 Dec 2025, 21:48 UTC

Market Talk

Hiring Confidence Slips in Canada Entering 2026 -- Market Talk

9 Dec 2025, 21:36 UTC

Earnings

Casey's General Stores: Fiscal 2026 EBITDA Is Expected to Increase 15% to 17% >CASY

9 Dec 2025, 21:36 UTC

Earnings

Casey's General Stores: Total Inside Gross Profit Increased 13.5% to $703.4M Compared to Prior Yr >CASY

9 Dec 2025, 21:36 UTC

Earnings

Casey's General Stores: Now Expects Inside Same-Store Sales to Increase 3% to 4% and an Inside Margin of 41% to 42% >CASY

9 Dec 2025, 21:36 UTC

Earnings

Casey's General Stores: Same-Store Fuel Gallons Up 0.8% Compared to Prior Yr With Fuel Margin of 41.6 Cents per Gallon, Total Fuel Gross Profit Increased 20.9% to $377.4M Compared to Prior Yr >CASY

9 Dec 2025, 21:36 UTC

Earnings

Casey's General Stores: Inside Same-Store Sales Increased 3.3% Compared to Prior Yr, and 7.5% on 2-Yr Stack Basis, With an Inside Margin of 42.4% >CASY

9 Dec 2025, 20:28 UTC

Market Talk

Oil Futures Decline for Second Straight Session -- Market Talk

9 Dec 2025, 20:27 UTC

Acquisitions, Mergers, Takeovers

Teck Resources: Merger of Equals With Anglo Amer Plc Approved by Both Classes of Teck Hldrs

9 Dec 2025, 20:27 UTC

Acquisitions, Mergers, Takeovers

Teck Reports Voting Results From Special Meeting of Hldrs

9 Dec 2025, 20:26 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Moody's: Paramount's Warner Bid Makes Strategic Sense, With Risk -- Market Talk

9 Dec 2025, 20:21 UTC

Market Talk

U.S. Natural Gas Extends Pullback on Shifting Weather Outlook -- Market Talk

9 Dec 2025, 19:52 UTC

Earnings

Correction to 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com on Dec. 8

9 Dec 2025, 19:17 UTC

Earnings

Update: 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com

9 Dec 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 Dec 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9 Dec 2025, 17:11 UTC

Earnings

Nvidia Has Permission to Sell H200 Chips to China. Why It Might Not Matter Much for the Stock. -- Barrons.com

Peer Comparison

Price change

Pliant Therapeutics Inc Forecast

Price Target

By TipRanks

134.38% upside

12 Months Forecast

Average 3 USD 134.38%

High 4 USD

Low 2 USD

Based on 4 Wall Street analysts offering 12 month price targets forPliant Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Pliant Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

1.43 / 1.6Support & Resistance

Recent bearish events outweigh bullish events.

There is one bearish event.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.